Quote:

Yep -- the most-damning element is that the Janssen product has the same issue.[/]

Agreed. Prior to reading this analysis, my working assumption was manufacturing QC issues meant variable amounts of the vaxx per dose like the problems with the old whole-cell Pertussis vaxx - some being loaded hot-clot-shots and some being watered down "accidental placebos." But that's a lot less likely if two different manufacturing techniques have the same AE curve.

That heavily implies the problem is in the RNA behavior, which is where Pfizer, Moderna and Jansen all converge. And yet is still somehow tied to what is in each dose. Either there's an accelerant/retardant contaminating some lots, or they're not as good at consistently replicating the RNA payload as they think.

That's a question - Jansen uses a different technique to get the RNA into the victim's cells, but do they use the same technique as Pfizer and Moderna to create the RNA payload in the first place?